Efficacy and Safety of Poziotinib in HER2 Exon 20 Insertion NSCLC Patients who Received at Least 2 Previous Systemic Therapies

被引：0
|
作者：
Le, X. [1 ]
Prelaj, A. [2 ]
Baik, C. [3 ]
Tchekmedyian, N. [4 ]
Leu, S. [5 ]
Bhat, G. [5 ]
Heymach, J. V. [1 ]
Cornelissen, R. [6 ]
机构：
[1] MD Anderson Canc Ctr, Houston, TX USA
[2] Ist Nazl Tumori Milano Fdn IRCCS, Milan, Italy
[3] Seattle Canc Ctr Alliance, Seattle, WA USA
[4] City Hope Natl Med Ctr, Irvine, CA USA
[5] Spectrum Pharmaceut, Irvine, CA USA
[6] Erasmus MC Canc Inst, Rotterdam, Netherlands
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
HER2; exon20; poziotinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA13.09
引用
收藏
页码：S147 / S148
页数：2
相关论文
共 50 条
  • [31] Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4)
    Cornelissen, Robin
    Prelaj, Arsela
    Sun, Sophie
    Baik, Christina
    Wollner, Mirjana
    Haura, Eric B.
    Mamdani, Hirva
    Riess, Jonathan W.
    Cappuzzo, Federico
    Garassino, Marina C.
    Heymach, John V.
    Socinski, Mark A.
    Leu, Szu-Yun
    Bhat, Gajanan
    Lebel, Francois
    Le, Xiuning
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (08) : 1031 - 1041
  • [32] Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial
    Elamin, Yasir Y.
    Robichaux, Jacqulyne P.
    Carter, Brett W.
    Altan, Mehmet
    Gibbons, Don L.
    Fossella, Frank, V
    Lam, Vincent K.
    Patel, Anisha B.
    Negrao, Marcelo, V
    Le, Xiuning
    Mott, Frank E.
    Zhang, Jianjun
    Feng, Lei
    Blumenschein, George, Jr.
    Tsao, Anne S.
    Heymach, John, V
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (07) : 702 - 709
  • [33] Poziotinib in non-small-cell lung cancer patients with HER2 exon 20 mutations: A pooled analysis of randomized clinical trials
    Wang, Bi-Cheng
    Kuang, Bo-Hua
    Liu, Xin-Xiu
    Lin, Guo-He
    MEDICINE, 2022, 101 (44) : E31337
  • [34] Poziotinib activity and durability of responses in previously treated EGFR exon 20 NSCLC patients - a Phase 2 study
    Le, Xiuning
    Goldman, Jonathan
    Clarke, Jeffrey
    Techekmedyian, Nishan
    Piotrowska, Zofia
    Chu, David
    Bhat, Gajanan
    Lebel, Francois
    Socinski, Mark
    CANCER RESEARCH, 2020, 80 (16)
  • [35] First-Line Therapy in NSCLC harbouring EGFR or HER2 Exon 20 Insertion Mutation. Hunting for the Best Candidate
    Prelaj, A.
    Bottiglieri, A.
    Lo Russo, G.
    Ferrara, R.
    Galli, G.
    De Toma, A.
    Brambilla, M.
    Occhipinti, M.
    Manglaviti, S.
    Beninato, T.
    Zattarin, E.
    Apollonio, G.
    Massa, G.
    Mazzeo, L.
    Galli, E.
    Dumitrascu, D.
    Ganzinelli, M.
    Gallucci, R.
    Di Mauro, R.
    Vitale, S.
    De Braud, F. G. M.
    Garassino, M. C.
    Proto, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1116 - S1117
  • [36] Investigating and Overcoming Primary Resistance of EGFR and HER2 (ERBB2) Exon 20 Mutant NSCLC
    Robichaux, J. P.
    Elamin, Y. Y.
    Vijayan, R. S. K.
    He, J.
    Hu, L.
    Zhang, F.
    Poteete, A.
    Pisegna, M.
    Nilsson, M. B.
    Sun, H.
    Negrao, M. V.
    Le, X.
    Raymond, V. M.
    Lanman, R. B.
    Frampton, G. M.
    Miller, V. A.
    Schrock, A. B.
    Cross, J. B.
    Wong, K.
    Heymach, J. V.
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (02) : S9 - S10
  • [37] Discovery and characterization of potent and selective HER2 exon20 insertion mutant inhibitors
    Nam, Ho Yeon
    Jang, Sun Young
    Jeon, Jiyoung
    Yoo, HyungSeok
    Byun, Jooyun
    Lee, Gunwoo
    Lee, Youngjoo
    Kim, Yu-Yon
    Jeon, Soye
    Ahn, Young Gil
    CANCER RESEARCH, 2024, 84 (06)
  • [38] HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib
    Zhang, Xinyong
    Lv, Jialin
    Wu, Yuhua
    Qin, Na
    Ma, Li
    Li, Xi
    Nong, Jingying
    Zhang, Hui
    Zhang, Quan
    Yang, Xinjie
    Shi, Huibo
    Wang, Jinghui
    Zhang, Shucai
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [39] First case report of sunvozertinib for the treatment of HER2 exon 20 insertion in lung adenocarcinoma
    Luan, Tao
    Lin, Xinqing
    Xie, Xiaohong
    Yang, Gang
    Wang, Shuaiying
    Hao, Jianqing
    Zhou, Chengzhi
    ANTI-CANCER DRUGS, 2024, 35 (08) : 757 - 760
  • [40] Safety, PK, and Preliminary Antitumor Activity of the Oral EGFR/HER2 Exon 20 Inhibitor TAK-788 in NSCLC
    Neal, J.
    Doebele, R.
    Riely, G.
    Spira, A.
    Horn, L.
    Piotrowska, Z.
    Costa, D.
    Zhang, S.
    Bottino, D.
    Zhu, J.
    Kerstein, D.
    Li, S.
    Janne, P.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S599 - S599
12345